Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2020-10-08 Declaration of Voting R…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a table detailing the total number of shares and total voting rights as of a specific date (September 30, 2020). This content directly relates to the disclosure of voting rights and share capital structure, which is a specific regulatory disclosure. Among the provided codes, none perfectly match a 'Monthly Voting Rights Disclosure'. However, the content is a specific regulatory announcement concerning share structure and voting rights, which is distinct from a dividend notice (DIV), director dealing (DIRS), or major shareholding notification (MRQ). Given the options, this type of disclosure, which is mandatory and relates to the capital structure and shareholder rights, is best categorized under 'Regulatory Filings' (RNS) as a general regulatory announcement, as there is no specific code for 'Voting Rights Disclosure'. The document is short and is a direct disclosure, not an announcement of a larger report.
2020-10-08 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital), referencing Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of September 30, 2020. This content directly relates to changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA), as it reports the current state of the capital base and associated voting power, often required monthly for listed companies.
2020-10-08 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen, dated October 8, 2020, announcing the presentation of 12 abstracts at the World Congress for NeuroRehabilitation (WCNR). It details the topics, including studies on spasticity and cervical dystonia treatments (Dysport/abobotulinumtoxinA), and provides context about the conditions and the company. This content is typical of a scientific or medical update intended for investors and the public, often released in conjunction with a major conference. It is not a formal regulatory filing (like 10-K or IR), nor is it a transcript (CT) or a formal earnings release (ER). It functions as an Investor Presentation (IP) or a specific type of scientific/medical announcement. Given the focus on presenting research findings at a specific medical congress, 'Investor Presentation' (IP) is the most fitting category, as these materials often serve as the basis for investor communications regarding R&D progress.
2020-10-08 French
Inside Information / Other news releases
Environmental & Social Information Classification · 1% confidence The document is a press release from Ipsen dated October 8, 2020, announcing the presentation of 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress. It details the titles, poster numbers, and session timings for these presentations, which focus on Ipsen's products (Dysport/abobotulinumtoxinA) for treating spasticity and cervical dystonia. This type of announcement, detailing scientific data presentations at a medical conference, is characteristic of an Investor Presentation (IP) or a general press release related to R&D/pipeline updates. Since it is not a formal regulatory filing (like 10-K, IR, ER), nor a management change (MANG) or dividend notice (DIV), and it is specifically presenting scientific findings intended for investors and the medical community, 'Investor Presentation' (IP) is the most fitting category, as these press releases often serve as the initial public disclosure of such data before or alongside a formal presentation document. However, given the options, this is a press release announcing scientific data being presented at a congress. While it contains information that might be in an IP, the document itself is structured as a news release detailing conference participation. If the content were a formal slide deck, IP would be correct. As a press release announcing abstract presentations, it often falls under general Investor Relations communication. Since it is not a formal financial report (10-K, IR, ER) or a specific regulatory filing (RNS), and it is providing detailed scientific/clinical updates aimed at investors, 'Investor Presentation' (IP) is chosen as the closest fit for communicating clinical trial/research progress to the investment community, even though it's a press release format. Revisiting the definitions: It is not a formal 'Earnings Release' (ER) or 'Interim Report' (IR). It is not a 'Report Publication Announcement' (RPA) because it is announcing participation in a congress, not the publication of a formal company report (like an Annual Report). Therefore, 'Investor Presentation' (IP) remains the best fit for communicating clinical/research milestones to investors.
2020-10-08 English
Inside Information / Other news releases
Transaction in Own Shares Classification · 1% confidence The document explicitly states 'Disclosure of transactions in own shares' and provides a detailed table showing the volume and price of shares acquired by the issuer (IPSEN) over specific dates (09/28/2020 to 10/02/2020). This directly corresponds to the definition of a report detailing the company buying back or selling its own shares. This matches the 'Transaction in Own Shares' category (POS). The document length is short (4035 chars) and it references where further information is available, but the core content *is* the transaction disclosure, not just an announcement of a report, making POS a better fit than RPA or RNS.
2020-10-06 English
Informations privilégiées / Autres communiqués
Transaction in Own Shares Classification · 1% confidence The document title explicitly states "Déclaration des transactions sur actions propres réalisées du 28/09/2020 au 02/10/2020" (Declaration of transactions on own shares carried out from 09/28/2020 to 10/02/2020). This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). The content is a detailed table summarizing the volume and price of these transactions. This matches filing type code POS.
2020-10-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.